Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 plus paclitaxel/carboplatin in first-line optimally debulked epithelial ovarian cancer
2008-001551-22Phase 2Completed
- Sponsor
- TRIO
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing AMG 479 + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started Aug 2008; status: completed.
02
Drugs
ganitumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-001551-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001551-22.